


Healthcare Industry News: HIV/AIDS
News Release - February 6, 2008
Merck's ISENTRESS(R) (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Source: Merck
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
